289 related articles for article (PubMed ID: 33894103)
21. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
22. Gender-Specific Differences in Serum Sphingomyelin Species in Patients with Hepatitis C Virus Infection-Sphingomyelin Species Are Related to the Model of End-Stage Liver Disease (MELD) Score in Male Patients.
Peschel G; Weigand K; Grimm J; Müller M; Krautbauer S; Höring M; Liebisch G; Buechler C
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176109
[TBL] [Abstract][Full Text] [Related]
23. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.
Drazilova S; Janicko M; Skladany L; Kristian P; Oltman M; Szantova M; Krkoska D; Mazuchova E; Piesecka L; Vahalova V; Rac M; Schreter I; Virag L; Koller T; Liptakova A; Ondrasova M; Jarcuska P
Can J Gastroenterol Hepatol; 2018; 2018():6095097. PubMed ID: 30402450
[TBL] [Abstract][Full Text] [Related]
24. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study.
Adinolfi LE; Petta S; Fracanzani AL; Nevola R; Coppola C; Narciso V; Rinaldi L; Calvaruso V; Pafundi PC; Lombardi R; Staiano L; Di Marco V; Solano A; Marrone A; Saturnino M; Rini F; Guerrera B; Troina G; Giordano M; Craxì A; Sasso FC
Diabetes Obes Metab; 2020 Dec; 22(12):2408-2416. PubMed ID: 32761721
[TBL] [Abstract][Full Text] [Related]
25. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
26. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis.
Carnovale C; Pozzi M; Dassano A; D'Addio F; Gentili M; Magni C; Clementi E; Radice S; Fiorina P
Acta Diabetol; 2019 Mar; 56(3):341-354. PubMed ID: 30478781
[TBL] [Abstract][Full Text] [Related]
27. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
28. Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C.
Li J; Gordon SC; Rupp LB; Zhang T; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Lu M;
Liver Int; 2019 Jun; 39(6):1027-1032. PubMed ID: 30570808
[TBL] [Abstract][Full Text] [Related]
29. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
30. Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study.
Thi Thu PN; Hoang Van D; Ngo Thi Quynh M; Tran Thi N; Pham Minh K; Pham Van L
PLoS One; 2023; 18(9):e0290235. PubMed ID: 37656689
[TBL] [Abstract][Full Text] [Related]
31. Viral eradication by direct-acting antivirals does not decrease the serum myostatin level in patients infected with hepatitis C virus.
Endo K; Sato T; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
Nutrition; 2022 Sep; 101():111699. PubMed ID: 35700590
[TBL] [Abstract][Full Text] [Related]
32. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
[TBL] [Abstract][Full Text] [Related]
33. Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance.
Peschel G; Krautbauer S; Weigand K; Grimm J; Höring M; Liebisch G; Müller M; Buechler C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256273
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
[TBL] [Abstract][Full Text] [Related]
35. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
[TBL] [Abstract][Full Text] [Related]
36. Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis.
Chen Y; Ji H; Shao J; Jia Y; Bao Q; Zhu J; Zhang L; Shen Y
Dig Dis Sci; 2020 Jul; 65(7):1940-1950. PubMed ID: 31758432
[TBL] [Abstract][Full Text] [Related]
37. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
38. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
39. HCV cirrhotic patients treated with direct-acting antivirals: Detection of tubular dysfunction and resolution after viral clearance.
Biliotti E; Palazzo D; Tinti F; D'Alessandro MD; Esvan R; Labriola R; Cappoli A; Umbro I; Volpicelli L; Bachetoni A; Villa E; Mitterhofer AP; Rucci P; Taliani G
Liver Int; 2021 Jan; 41(1):158-167. PubMed ID: 32979012
[TBL] [Abstract][Full Text] [Related]
40. [The impact of direct-acting antiviral therapy on the diagnosis of hepatitis-C virus-associated hepatocellular carcinoma].
Takahashi A; Shima T; Kinoshita N; Yano K; Ueno T; Nishiwaki M; Yamamoto Y; Oya H; Amano I; Matsumoto J; Mitsumoto Y; Tanaka I; Sakai K; Sawai N; Mizuno C; Mizuno M; Itoh Y; Okanoue T
Nihon Shokakibyo Gakkai Zasshi; 2018; 115(2):184-194. PubMed ID: 29459562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
